222 related articles for article (PubMed ID: 23260655)
1. Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding.
Leach BI; Kuntimaddi A; Schmidt CR; Cierpicki T; Johnson SA; Bushweller JH
Structure; 2013 Jan; 21(1):176-183. PubMed ID: 23260655
[TBL] [Abstract][Full Text] [Related]
2. The Intrinsically Disordered Proteins MLLT3 (AF9) and MLLT1 (ENL) - Multimodal Transcriptional Switches With Roles in Normal Hematopoiesis, MLL Fusion Leukemia, and Kidney Cancer.
Kabra A; Bushweller J
J Mol Biol; 2022 Jan; 434(1):167117. PubMed ID: 34174329
[TBL] [Abstract][Full Text] [Related]
3. Structural studies of intrinsically disordered MLL-fusion protein AF9 in complex with peptidomimetic inhibitors.
Yang Y; Ahmad E; Premkumar V; Liu A; Ashikur Rahman SM; Nikolovska-Coleska Z
Protein Sci; 2024 Jun; 33(6):e5019. PubMed ID: 38747396
[TBL] [Abstract][Full Text] [Related]
4. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
[TBL] [Abstract][Full Text] [Related]
5. Domains with transcriptional regulatory activity within the ALL1 and AF4 proteins involved in acute leukemia.
Prasad R; Yano T; Sorio C; Nakamura T; Rallapalli R; Gu Y; Leshkowitz D; Croce CM; Canaani E
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12160-4. PubMed ID: 8618864
[TBL] [Abstract][Full Text] [Related]
6. Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology.
Watson VG; Drake KM; Peng Y; Napper AD
Assay Drug Dev Technol; 2013 May; 11(4):253-68. PubMed ID: 23679849
[TBL] [Abstract][Full Text] [Related]
7. MLL fusion partners AF4 and AF9 interact at subnuclear foci.
Erfurth F; Hemenway CS; de Erkenez AC; Domer PH
Leukemia; 2004 Jan; 18(1):92-102. PubMed ID: 14603337
[TBL] [Abstract][Full Text] [Related]
8. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.
Kuntimaddi A; Achille NJ; Thorpe J; Lokken AA; Singh R; Hemenway CS; Adli M; Zeleznik-Le NJ; Bushweller JH
Cell Rep; 2015 May; 11(5):808-20. PubMed ID: 25921540
[TBL] [Abstract][Full Text] [Related]
9. An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias.
Barretto NN; Karahalios DS; You D; Hemenway CS
J Exp Ther Oncol; 2014; 10(4):293-300. PubMed ID: 25509985
[TBL] [Abstract][Full Text] [Related]
10. The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor.
Srinivasan RS; de Erkenez AC; Hemenway CS
Oncogene; 2003 May; 22(22):3395-406. PubMed ID: 12776190
[TBL] [Abstract][Full Text] [Related]
11. Collaboration of MLLT1/ENL, Polycomb and ATM for transcription and genome integrity.
Ui A; Yasui A
Nucleus; 2016 Apr; 7(2):138-45. PubMed ID: 27310306
[TBL] [Abstract][Full Text] [Related]
12. The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells.
Srinivasan RS; Nesbit JB; Marrero L; Erfurth F; LaRussa VF; Hemenway CS
Leukemia; 2004 Aug; 18(8):1364-72. PubMed ID: 15269783
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between 14-3-3θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation.
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Salvatore F; Esposito G
Cell Oncol (Dordr); 2019 Dec; 42(6):829-845. PubMed ID: 31493143
[TBL] [Abstract][Full Text] [Related]
14. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
Monroe SC; Jo SY; Sanders DS; Basrur V; Elenitoba-Johnson KS; Slany RK; Hess JL
Exp Hematol; 2011 Jan; 39(1):77-86.e1-5. PubMed ID: 20854876
[TBL] [Abstract][Full Text] [Related]
15. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
[TBL] [Abstract][Full Text] [Related]
16. Biophysical Analysis of the N-Terminal Domain from the Human Protein Phosphatase 1 Nuclear Targeting Subunit PNUTS Suggests an Extended Transcription Factor TFIIS-Like Fold.
Zacharchenko T; Barsukov I; Rigden DJ; Bennett D; Mayans O
Protein J; 2016 Oct; 35(5):340-345. PubMed ID: 27591855
[TBL] [Abstract][Full Text] [Related]
17. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
18. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.
Yokoyama A; Lin M; Naresh A; Kitabayashi I; Cleary ML
Cancer Cell; 2010 Feb; 17(2):198-212. PubMed ID: 20153263
[TBL] [Abstract][Full Text] [Related]
19. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.
Muntean AG; Tan J; Sitwala K; Huang Y; Bronstein J; Connelly JA; Basrur V; Elenitoba-Johnson KS; Hess JL
Cancer Cell; 2010 Jun; 17(6):609-21. PubMed ID: 20541477
[TBL] [Abstract][Full Text] [Related]
20. Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia.
Super HG; Strissel PL; Sobulo OM; Burian D; Reshmi SC; Roe B; Zeleznik-Le NJ; Diaz MO; Rowley JD
Genes Chromosomes Cancer; 1997 Oct; 20(2):185-95. PubMed ID: 9331569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
